Aspirin and similar drug use linked to lower endometrial cancer risk in overweight women

Published: Comments:
Health & Wellness Lifestyle Science & Research


A study by QIMR Berghofer researchers has found that overweight and obese women who take aspirin at least once a week may reduce their risk of developing endometrial cancer (cancer of the womb).

Women who are overweight or obese are up to five times more likely to develop the cancer than women whose body weight is in the healthy range.

Study author and head of QIMR Berghofer’s Gynaecological Cancers group, Professor Penny Webb, said the analysis of data from more than 23,000 women suggested regular use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen might reduce the risk of endometrial cancer in overweight women.

“Previous studies have linked regular use of aspirin with a reduced risk of diseases such as bowel cancer, but the data for endometrial cancer were conflicting,” Professor Webb said.

“Our research found that overweight and obese women who took aspirin, ibuprofen or other NSAIDs more than once a week had about a 15 per cent lower risk of developing endometrial cancer than overweight women who did not use these medicines.”

Seven Australian women are diagnosed with endometrial cancer every day, and one in five women who develop the disease will die within five years, according to statistics from the Australian Institute of Health and Welfare.

The study found no association with cancer risk for women who were overweight or obese who took a daily dose of aspirin, Professor Webb said.

“That’s probably because most of that group were taking low dose aspirin to prevent heart disease, and it is possible the lower dose was not sufficient to have an effect on cancer risk,” Professor Webb said.

“We think regular use of anti-inflammatory drugs like aspirin may reduce the cancer risk in overweight women because obesity is associated with chronic inflammation, which may increase cancer risk.

“Other studies have suggested that women who take aspirin and NSAIDs have lower oestrogen levels and we know oestrogen plays a significant role in the development of endometrial cancer.”

The study found no association between use of the medications and endometrial cancer risk among women with a normal body weight.

It also found no association between use of paracetamol and endometrial cancer risk.

Professor Webb said further research was needed into the role anti-inflammatory drugs might play in preventing endometrial cancer but, if the link was confirmed,  doctors could consider prescribing aspirin or NSAIDs as an option to reduce the risk of the disease among obese women who have not had a hysterectomy.

“It’s important to remember that these medicines can have negative side effects so women should talk to their GP before taking them regularly,” she said.

“Endometrial cancer rates are continuing to rise as obesity rates increase, so we need to examine options for treating and preventing this disease.”

The study examined data from seven cohort and five case–control studies participating in the international Epidemiology of Endometrial Cancer Consortium, including 7120 women with endometrial cancer and 16 069 controls.

The paper has been published in the journal Annals of Oncology.

QIMR Berghofer Medical Research Institute :
PO Royal Brisbane Hospital, Brisbane, QLD, 4029, Brisbane
07 3845 3752
QIMR Berghofer Medical Research Institute
Showing 10+ recent articles for this business
Aspirin and similar drug use linked to lower endometrial cancer risk in overweight women 07 March 2019 | A study by QIMR Berghofer researchers has found that overweight and obese women who take aspirin at least once a week may reduce their risk of developing endometrial cancer (cancer of the womb). More information...
Safer bone marrow transplants for blood cancer patients a step closer 15 February 2019 | Queensland researchers have conducted Australia’s first clinical trial using genetically engineered immune cells to make bone marrow transplantation for blood cancer safer. More information...
New study finds hysterectomies reduce the risk of ovarian cancer in some women 12 February 2019 | A new study by QIMR Berghofer researchers has found women who suffer from endometriosis or uterine fibroids and who undergo hysterectomies have a significantly lower risk of developing ovarian cancer than those... More information...
Australia’s melanoma rates once again highest in the world 07 February 2019 | Australia has regained the unenviable title of having the world’s highest rates of invasive melanoma. More information...
Peak health bodies recommend new approach to sunscreen use 25 January 2019 | The peak bodies responsible for sun safety advice in Australia and New Zealand have adopted a new policy on sunscreen use, recommending that people apply it daily as part of a regular morning routine. More information...
Study gives hope for preventing life-threatening viral infections in transplant patients 18 January 2019 | Australian researchers have made a breakthrough in understanding how a common herpes virus reactivates and causes life-threatening complications in patients with compromised immune systems. More information...
Queensland scientists create functioning human muscle in a dish 10 December 2018 | QIMR Berghofer researchers have created functioning miniature human skeletal muscle – a move that will accelerate research into muscle disease and treatments. More information...
Discovery holds promise for a new oesophageal cancer screening test 04 December 2018 | One of Australia’s most deadly cancers could in future be detected earlier, and with a simple blood test, thanks to research from QIMR Berghofer Medical Research Institute. More information...
QIMR Berghofer helps map the genetic makeup of disease-spreading mosquito 22 November 2018 | QIMR Berghofer scientists have helped map the most complete genetic picture of the potentially deadly Aedes aegypti mosquito. More information...
Clinical trial finds new immunotherapy improves MS symptoms 20 November 2018 | A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has found that it improved symptoms and quality of life for the majority of patients. More information...

comments powered by Disqus

All articles submitted by third parties or written by My Sunshine Coast come under our Disclaimer / Terms of Service